Related Experiment Video

Updated: Jul 2, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or

Maria Victoria Mateos1, Katja Weisel2, Evangelos Terpos3

  • 1Hospital Universitario de Salamanca, Spain; University of Salamanca. mvmateos@usal.es.

Haematologica
|February 22, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Related Experiment Videos

Last Updated: Jul 2, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

Articles linked to this work by shared authors, journal, and citation graph.

Circulating tumor plasma cells quantification in newly diagnosed transplant ineligible real world multiple myeloma patients: Comparison of single-platform flow cytometry versus next generation flow.

Cytometry. Part B, Clinical cytometry·2026

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.

Frontiers in oncology·2026

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Cells·2026

Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.

Haematologica·2026

Case Report: Iatrogenic dyspnea and respiratory failure in a multiple myeloma patient treated with carfilzomib.

Frontiers in oncology·2025

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.

HemaSphere·2025

Response to Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia".

Haematologica·2026

Salvage of primary graft failure with allogeneic hematopoietic stem cell transplantation from a deceased organ donor: report of a novel graft source.

Haematologica·2026

Philadelphia chromosome-like acute lymphoblastic leukemia: treat intensively, transplant selectively.

Haematologica·2026

The role of CHIP and pre-treatment neutropenia in patients treated with chimeric antigen receptor T cells for hematological malignancies.

Haematologica·2026

Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib.

Haematologica·2026

CD25-based graft-versus-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies.

Haematologica·2026

Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety.

Frontiers in medicine·2026

Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis.

Genes to cells : devoted to molecular & cellular mechanisms·2026

Inhibition of the NR4A1-mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity.

British journal of pharmacology·2026

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

Leukemia·2026

Integrated morphological and transcriptomic analysis of bone disorders in aldosterone-salt hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

TFAM loss drives oxaliplatin resistance by linking mtDNA release to STING-TBK1-mediated lysophagy.

Oncogene·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us